---
title: "JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287084364.md"
description: "Jupiter Neurosciences, Inc. (JUNS) experienced its largest single-day gain in nearly a year, surging over 50% after securing a $100 million licensing deal for the MDMA-based drug ALA-002. The agreement includes a $3.3 million upfront payment and positions JUNS to capitalize on the growing psychedelic therapeutics market. Retail sentiment has turned extremely bullish, with expectations for shares to reach $1 despite a 60% decline this year."
datetime: "2026-05-20T14:35:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287084364.md)
  - [en](https://longbridge.com/en/news/287084364.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287084364.md)
---

# JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

・The agreement carries a potential value of up to $100 million, but Jupiter will make an upfront payment of $3.3 million. ・ALA-002 is a patented MDMA formulation recognized by the U.S. Food and Drug Administration as a novel chemical entity. ・JUNS stock is set to test a key technical milestone for the first time in nearly seven months. Shares of Ju...

### Related Stocks

- [JUNS.US](https://longbridge.com/en/quote/JUNS.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)